Teva Pharmaceutical Industries Limited Stock
Stocks
TEVA
US8816242098
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.03 USD | -0.59% |
|
-2.79% | +2.63% |
| 07-09 | Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus | MT |
| 07-09 | Teva, Samsung Bioepis Partner to Commercialize Eylea Biosimilar Opuviz in Canada | MT |
| Market Cap | 37.3B 32.64B 30.16B 27.74B 52.29B 3,591B 53.47B 359B 141B 1,755B 140B 137B 6,061B | P/E 2026 * |
39.5x | P/E 2027 * | 17.4x |
|---|---|---|---|---|---|
| Enterprise Value | 48.48B 42.43B 39.2B 36.06B 67.97B 4,667B 69.51B 467B 184B 2,282B 182B 178B 7,878B | EV / Sales 2026 * |
2.91x | EV / Sales 2027 * | 2.65x |
| Free-Float |
88.61% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Teva Pharmaceutical Industries Limited
| 1 day | -0.59% | ||
| 1 week | -2.79% | ||
| Current month | -5.46% | ||
| 1 month | +1.75% | ||
| 3 months | -1.14% | ||
| 6 months | +0.85% | ||
| Current year | +2.63% |
| 1 week | 31.28 |  | 32.81 |
| 1 month | 31.28 | | 35.47 |
| Current year | 27.93 | | 37.34 |
| 1 year | 14.99 | | 37.34 |
| 3 years | 8.06 | | 37.34 |
| 5 years | 6.78 | | 37.34 |
| 10 years | 6.07 | | 55.79 |
| Manager | Title | Age | Since |
|---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 57 | 01/01/2023 |
Eli Kalif
DFI | Director of Finance/CFO | 53 | 22/12/2019 |
Matthew Shields
COO | Chief Operating Officer | 52 | 03/06/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Amir Elstein
BRD | Director/Board Member | 69 | 01/01/2009 |
Sol Barer
CHM | Chairman | 78 | 06/02/2017 |
Rosemary Crane
BRD | Director/Board Member | 65 | 01/09/2015 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/18/26 A | Sell | Chief Operating Officer | -9,989 | 0.0009% | ||
| 6/11/26 A | Sell | Chief Financial Officer | -106,563 | 0.0091% | ||
| 6/5/26 A | Fiscal year | Director | 28,984 | 0.0025% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.59% | -2.79% | +99.44% | +293.97% | 37.3B | |
| +0.85% | -0.80% | +52.79% | +161.33% | 1,051B | |
| +1.23% | -1.53% | +54.58% | +59.08% | 609B | |
| +0.04% | +2.58% | +34.47% | +86.33% | 450B | |
| +0.78% | -0.71% | +29.28% | +24.10% | 330B | |
| +1.41% | +0.58% | +35.44% | +40.67% | 284B | |
| -0.27% | -1.87% | +22.34% | +22.51% | 263B | |
| -1.76% | +2.37% | -20.43% | -38.00% | 223B | |
| -1.42% | +0.80% | +24.27% | +57.50% | 198B | |
| -1.48% | +3.43% | +24.08% | +71.67% | 167B | |
| Average | -0.12% | +0.22% | +35.63% | +77.92% | 361.24B | |
| Weighted average by Cap. | +0.36% | -0.00% | +38.15% | +81.84% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.64B 14.57B 13.46B 12.38B 23.33B 1,602B 23.86B 160B 63.08B 783B 62.5B 61.13B 2,705B | 17.24B 15.09B 13.94B 12.82B 24.17B 1,660B 24.72B 166B 65.34B 811B 64.74B 63.32B 2,801B |
| Net income | 1.54B 1.35B 1.25B 1.15B 2.16B 149B 2.21B 14.87B 5.85B 72.61B 5.79B 5.67B 251B | 2.46B 2.16B 1.99B 1.83B 3.45B 237B 3.53B 23.74B 9.34B 116B 9.25B 9.05B 400B |
| Net Debt | 11.18B 9.79B 9.04B 8.32B 15.68B 1,077B 16.03B 108B 42.39B 526B 42B 41.07B 1,817B | 8.44B 7.38B 6.82B 6.27B 11.83B 812B 12.09B 81.29B 31.97B 397B 31.68B 30.98B 1,371B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | $32.03 | -0.59% | 3,612,359 |
| 16/07/26 | $32.22 | +2.09% | 4,453,698 |
| 15/07/26 | $31.56 | -0.82% | 5,519,683 |
| 14/07/26 | $31.82 | -1.12% | 3,452,186 |
| 13/07/26 | $32.18 | -2.34% | 4,231,527 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- TEVA Stock
Select your edition
All financial news and data tailored to specific country editions
